Alterations in Cognitive Function and Cerebral Blood Flow After Conversion From Immediate Release Tacrolimus to Slow Release Envarsus
Sponsor: University of Kansas Medical Center
Listed as NCT03703154, this observational or N/A phase trial focuses on End Stage Renal Disease and remains completed. Sponsored by University of Kansas Medical Center, it has been updated 12 times since 2018, reflecting substantial change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
12 versions recorded-
Sep 2024 — Present [monthly]
Completed
-
Jul 2024 — Sep 2024 [monthly]
Completed
-
Dec 2021 — Jul 2024 [monthly]
Completed
-
May 2021 — Dec 2021 [monthly]
Completed
Status: Active Not Recruiting → Completed
-
Apr 2021 — May 2021 [monthly]
Active Not Recruiting
Status: Recruiting → Active Not Recruiting
▶ Show 7 earlier versions
-
Jan 2021 — Apr 2021 [monthly]
Recruiting
-
Nov 2020 — Jan 2021 [monthly]
Recruiting
-
Oct 2020 — Nov 2020 [monthly]
Recruiting
-
Jan 2020 — Oct 2020 [monthly]
Recruiting
-
Nov 2019 — Jan 2020 [monthly]
Recruiting
-
Jan 2019 — Nov 2019 [monthly]
Recruiting
-
Nov 2018 — Jan 2019 [monthly]
Recruiting
First recorded
Oct 2018
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- University of Kansas Medical Center
- Veloxis Pharmaceuticals
For direct contact, visit the study record on ClinicalTrials.gov .